Lopes AS, Basto R, Henriques S, Colaço L, Costa E Silva F, Prieto I, Guerreiro F, et al.
Case reports in ophthalmological medicine. Date of publication 2019 Dec 28;volume 2019():9765938.
1. Case Rep Ophthalmol Med. 2019 Dec 28;2019:9765938. doi: 10.1155/2019/9765938.
eCollection 2019.
Hyperbaric Oxygen Therapy in Retinal Arterial Occlusion: Epidemiology, Clinical
Approach, and Visual Outcomes.
Lopes AS(1), Basto R(1), Henriques S(1), Colaço L(1), Costa E Silva F(1), Prieto
I(1), Guerreiro F(2).
Author information:
(1)Department of Ophthalmology of Professor Doutor Fernando Fonseca E.P.E.
Hospital (Amadora-Sintra), Lisbon, Portugal.
(2)Underwater and Hyperbaric Medicine Center, Armed Forces Hospital-Lisbon Pole,
Lisbon, Portugal.
PURPOSE: To evaluate the efficacy and safety of hyperbaric oxygen therapy (HBOT)
in patients with acute retinal artery occlusion (RAO). Secondarily, to analyse
the epidemiology and the clinical approach.
METHODS: Retrospective study of 13 patients submitted to HBOT between 2013 and
2018. The analysed parameters consisted of: systemic history, time between
symptoms onset and treatment, initial approach, number of HBOT sessions,
complications of HBOT and best corrected visual acuity-BCVA (of the total
sample, central RAO-CRAO-group, and branch RAO-BRAO group).
RESULTS: Arterial hypertension was the most prevalent systemic risk factor
(53.8%). Initial therapies were 100% normobaric oxygen administration, topical
and oral hypotensive medication, eye massage and aspirin. CRAO was observed in
69.2% and BRAO in 30.8% of the cases, with clinically significant visual
improvement (a decrease in logMAR of 0.3) in 55.5% and 75%, respectively. Time
between symptoms onset and treatment had a median of 9 hours. The median number
of HBOT sessions was 7, without complications.
CONCLUSIONS: HBOT provide BCVA improvement in patients with RAO, when it is
performed in an early time after the symptom onset. It seems to be an effective
and safe therapeutic option for a pathology that still remains without approved
treatment.
Copyright © 2019 Ana Sofia Lopes et al.
DOI: 10.1155/2019/9765938
PMCID: PMC7012270
PMID: 32089924
Conflict of interest statement: The authors declare that they have no conflicts
of interest.
